The drug targeted inflammation, and its shocking failure has experts questioning whether inflammation really does cause heart disease.
Category: Novo Nordisk A/S
-
A Promising Heart Drug Fails, Challenging a Long-Held Theory of Disease
The New York Times – Business: -
Medicare Coverage for GLP-1 Weight Loss Drugs: Cost, Eligibility and What to Know
The New York Times – Business:What you should know about the federal government’s pilot program offering GLP-1s solely for weight loss.
-
Ozempic Is About to Go Generic in India, China and Canada
The New York Times – Business:In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.
-
Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials
The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a number of brain diseases.
-
Kennedy Walks a Tightrope on Trump Deal for Obesity Drugs
The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the president.
-
Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal
The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy.
-
What Trump’s New Drug Pricing Deal Means for People With Obesity
The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.
-
Obesity Drugs May Drop to as Little as $150 a Month
President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.
-
Costco to Sell Ozempic and Wegovy, Weight-Loss Wonder Drugs
Costco members will pay $499 a month out of pocket, the same price offered at CVS and Walmart, and on the manufacturer’s direct-to-consumer website.
-
How Private Equity Oversees the Ethics of Drug Research
Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.
-
Novo Nordisk’s Woes Are Slimming Denmark’s Economic Growth
Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too.
-
Ozempic Maker Novo Nordisk to Cut 9,000 Jobs
The Danish drugmaker said it needed to streamline operations and become more agile, as it faces a more competitive and consumer-focused market.